MedTrace Logo

Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma

NCT00280007 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2010-04-22

No results posted yet for this study

Summary

Patients with liver cirrhosis and hepatocellular carcinoma will undergo transarterial chemoembolisation (TACE) as clinically indicated and will be randomized to receive bevacizumab or placebo every 2 weeks up to 1 year. Tumor response will be assessed using MR of the liver and PET-scanning.

It will be tested whether the addition of bevacizumab as angiogenic inhibitor will slow down tumor progression, reduce the need for re-embolisation and will improve patient survival.

Conditions

Interventions

DRUG

bevacizumab

bevacizumab 5 mg/kg i.v. every 14 days for 52 weeks

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Markus Peck-Radosavljevic, M.D. · Medical University of Vienna

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2009-12-31
Completion
2010-12-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00280007 on ClinicalTrials.gov